Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Soheil Meshinchi

Showing results (71-80 of 218) with videos related to

Pageof 22
Sort By:
Blood|August 17, 2006
Clinical implications of FLT3 mutations in pediatric AMLSoheil Meshinchi, Todd A Alonzo, Derek L Stirewalt, et al.
Cancer|February 22, 2017
Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trialsXiaoyu Qu, Megan Othus, Jerry Davison, et al.
Blood|December 13, 2006
Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961Draga Barbaric, Todd A Alonzo, Robert B Gerbing, et al.
Oncotarget|June 2, 2016
Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemiaGeorge S Laszlo, Kimberly H Harrington, Chelsea J Gudgeon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2015
Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology GroupKatherine Tarlock, Todd A Alonzo, Robert B Gerbing, et al.
British Journal of Haematology|March 26, 2014
Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncology GroupKatherine Tarlock, Todd A Alonzo, Pilar Palomo Moraleda, et al.
British Journal of Haematology|November 28, 2008
Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemiaDeepika Bhatla, Robert B Gerbing, Todd A Alonzo, et al.
Research Square|March 30, 2023
DRPPM-PATH-SURVEIOR: Plug-and-Play Survival Analysis of Pathway-level Signatures and Immune ComponentsAlyssa Obermayer, Darwin Chang, Gabrielle Nobles, et al.
Biorxiv : the Preprint Server for Biology|November 26, 2025
Acute Myeloid Leukemia Relapse after Bromodomain Inhibitor Treatment or Chemotherapy is Characterized by Myc-Ras Transcriptional RemodelingBenjamin J Huang, Jeevitha D'Souza, Alexa Rane Batingana, et al.
Nature Communications|October 30, 2024
MLL oncoprotein levels influence leukemia lineage identitiesDerek H Janssens, Melodie Duran, Dominik J Otto, et al.
Pageof 22

Showing results (71-80 of 218) with videos related to

Sort By:
Pageof 22
Blood|August 17, 2006
Clinical implications of FLT3 mutations in pediatric AMLSoheil Meshinchi, Todd A Alonzo, Derek L Stirewalt, et al.
Cancer|February 22, 2017
Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trialsXiaoyu Qu, Megan Othus, Jerry Davison, et al.
Blood|December 13, 2006
Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961Draga Barbaric, Todd A Alonzo, Robert B Gerbing, et al.
Oncotarget|June 2, 2016
Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemiaGeorge S Laszlo, Kimberly H Harrington, Chelsea J Gudgeon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2015
Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology GroupKatherine Tarlock, Todd A Alonzo, Robert B Gerbing, et al.
British Journal of Haematology|March 26, 2014
Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncology GroupKatherine Tarlock, Todd A Alonzo, Pilar Palomo Moraleda, et al.
British Journal of Haematology|November 28, 2008
Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemiaDeepika Bhatla, Robert B Gerbing, Todd A Alonzo, et al.
Research Square|March 30, 2023
DRPPM-PATH-SURVEIOR: Plug-and-Play Survival Analysis of Pathway-level Signatures and Immune ComponentsAlyssa Obermayer, Darwin Chang, Gabrielle Nobles, et al.
Biorxiv : the Preprint Server for Biology|November 26, 2025
Acute Myeloid Leukemia Relapse after Bromodomain Inhibitor Treatment or Chemotherapy is Characterized by Myc-Ras Transcriptional RemodelingBenjamin J Huang, Jeevitha D'Souza, Alexa Rane Batingana, et al.
Nature Communications|October 30, 2024
MLL oncoprotein levels influence leukemia lineage identitiesDerek H Janssens, Melodie Duran, Dominik J Otto, et al.
Pageof 22